The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA

 
• By Cole Werble

Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.

US FDA entrance
FDA Building 1 actually uses dual sliding doors, which are good for climate control and emergency egress, but perhaps not as effective when it comes to metaphors. • Source: Alamy

More from US FDA

More from Agency Leadership